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Abstract
Background: Varicella-zoster virus (VZV) causes chickenpox in children and shingles in older people. Currently, live
attenuated vaccines based on the Oka strain are available worldwide. In Korea, an attenuated VZV vaccine has
been developed from a Korean isolate and has been commercially available since 1994. Despite this long history of
use, the mechanism for the attenuation of the vaccine strain is still elusive. We attempted to understand the
molecular basis of attenuation mechanism by full genome sequencing and comparative genomic analyses of the
Korean vaccine strain SuduVax.
Results: SuduVax was found to contain a genome that was 124,759 bp and possessed 74 open reading frames
(ORFs). SuduVax was genetically most close to Oka strains and these Korean-Japanese strains formed a strong clade
in phylogenetic trees. SuduVax, similar to the Oka vaccine strains, underwent T- > C substitution at the stop codon
of ORF0, resulting in a read-through mutation to code for an extended form of ORF0 protein. SuduVax also shared
certain deletion and insertion mutations in ORFs 17, 29, 56 and 60 with Oka vaccine strains and some clinical
strains.
Conclusions: The Korean VZV vaccine strain SuduVax is genetically similar to the Oka vaccine strains. Further
comparative genomic and bioinformatics analyses will help to elucidate the molecular basis of the attenuation of
the VZV vaccine strains.
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Background
Varicella-zoster virus (VZV) is an alpha-herpesvirus and
the cause of chickenpox (varicella) and shingles (zoster).
Chickenpox is characterized by fever and generalized rash,
and is most prevalent in children due to primary infection.
VZV can establish a latent infection in nerve cells of dorsal
root ganglia and its reactivation from latency causes shin-
gles in older adults and in immunocompromised people.
Isolation and propagation of VZV in cell culture was
first reported in 1953 [1], and the first determination of
the complete nucleotide sequence was made from the
Dumas strain [2]. As of August 2010, complete nucleo-
tide sequences had been determined and were available
from NCBI GenBank database from 23 VZV strains
including three vaccine strains derived from the Oka
strain. Comparison of the full nucleotide sequences of
clinical with vaccine strains has enabled researchers to
suggest putative regions that might be responsible for
attenuation in vaccine strains [3-6].
In Korea, the pharmaceutical company GCC has been
manufacturing an attenuated VZV vaccine for chickenpox
since 1994. The live-attenuated vaccine strain, SuduVax®,
was obtained through serial passage of wild-type virus in
cell culture. The original wild-type virus was isolated in
primary human embryonic lung (HEL) cell culture from a
33-month-old boy with chickenpox in 1989 in Seoul,
Korea [7]. The virus was attenuated by 10 passages in HEL
cells, 12 passages in guinea pig embryonic lung cells, and
passaged five times in HEL cells to prepare an attenuated
strain, designated MAV06, for vaccine production [8]. The
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attenuated viruses were stored in liquid nitrogen (master
virus banks). Working virus banks are routinely produced
after five passages of master virus bank stocks in HEL
cells. The final vaccine (SuduVax) is manufactured after
passaging of the working virus bank five times in HEL
cells.
SuduVax has been marketed in Korea since 1994 and
internationally since 1998. Although the efficacy and
safety of SuduVax have been proved in the marketplace,
molecular studies explaining the mechanism of attenua-
tion or the efficacy of the vaccine have not been available.
In this study, the complete nucleotide sequence of Sudu-
Vax was determined and compared with those of 23 VZV
strains whose full genomic sequences are registered in
the NCBI GenBank database.
Results
Overall genome structure of the Korean vaccine strain
SuduVax
The genome of the VZV strain SuduVax was determined
to be 124,759 bp. The architecture of the SuduVax gen-
ome is typical of VZV in that the genome could be divided
into TRL, UL, IRL, IRS, US and TRS (88, 104,799, 88,
7,276, 5,232, and 7276 bp, respectively). The G + C con-
tent of the SuduVax genome is approximately 46.1%. The
lengths of the genome, lengths of each region and the G +
C contents are very similar among the 24 VZV strains
analyzed in this study (Table 1). The SuduVax genome
contains 74 ORFs. Of these 64 are UL genes and four are
US genes. Three genes in IRS (ORFs 62-64) are inversely
repeated in TRS (ORFs 69-71). Of the 74 ORFs, 39 are in
the forward direction and 35 are in the reverse direction.
The directions of ORFs are 100% conserved among the
analyzed VZV strains. The ORF map of strain SuduVax is
presented in Figure 1.
Phylogenetic analysis
Phylogenetic trees were constructed using the full nucleo-
tide sequences of SuduVax and 23 VZV strains whose full
genomic DNA sequences are known. As shown in an
unrooted tree generated by maximum-likelihood method,
SuduVax and four Oka strains (pOka, vOka, VarilRix, Var-
iVax) formed a clade and strains M2DR and 8 formed an
adjacent clade (Figure 2a). These two clades were joined
with the clade whose member was the strain CA123 only.
Strains 11, 22, 03-500 and HJ0 formed another clade and
the rest of the clinical strains formed the last clade. Almost
identical topology was observed in a tree generated by
neighbour-joining method (data not shown) and Bayesian
method [9]. SuduVax together with Oka strains formed a
distinctive clade, corresponding to clade 2 proposed by the
VZV Nomenclature Meeting 2008 [10]. When trees were
constructed with concatenated coding nucleotide
sequences (ORF) or amino acid sequences, similar tree
topologies were obtained (data not shown). Next, we tried
to build phylogenetic trees using non-coding sequences.
Again, SuduVax grouped with four Oka strains, forming
clade 2 (Figure 2b). One notable difference between the
trees built by full or coding sequences and the tree built
by non-coding sequences was the location of pOka, the
parental Oka strain from which vaccine strain vOka was
derived. While pOka was located between the four vaccine
strains and 19 clinical strains in the tree built by full or
coding sequences, pOka was buried among the vaccine
strains in tree built by non-coding sequences (compare
Figures 2a, b). In other words, four vaccine strains (vOka,
VarilRix, VariVax, and SuduVax) formed a subclade within
the clade 2 in the trees built by full or coding sequences
(bootstrap value = 1,000 in neighbour-joining trees), but
not in the tree built by non-coding sequences.
In order to find which ORFs are important in distin-
guishing vaccine strains from clinical strains, further phy-
logentic analyses using individual ORF were performed.
Of the 74 phylogenetic trees, 12 ORF trees exhibited
clear branches leading to a formation of clusters consist-
ing of vaccine strains. These 12 ORFs included ORF 0, 1,
6, 18, 31, 35, 39, 59, 62, 64, 69 and 71 (Figure 2c). The
bootstrap values for vaccine clusters were greater than
640. In majority of ORF trees, vaccine clusters formed
subclades within clade 2. However, in phylogenetic trees
based on ORFs 1, 18, 39 and 59, branches leading to
clade 2 were not present or very short with low bootstrap
values (Figure 2d). Thus, the vaccine strains did not
always form a subclade within clade 2.
Evolutionary relationships between the Korean vaccine
strain SuduVax and other VZV strains were investigated
by calculating genetic distances among the 24 VZV strains.
As a whole, VZV genome sequences were highly con-
served among the strains. At the level of full nucleotide
sequences, SuduVax was the most similar to VarilRix, fol-
lowed by vOka, VariVax and pOka (Table 2). Similar
results were obtained when the genetic distances were cal-
culated using concatenated non-coding nucleotide
sequences or amino acid sequences. The average distance
between SuduVax and three vaccine strains at the full
nucleotide level was calculated to be 0.20 ± 0.05 × 10-3,
which was < 10% of the average distance between Sudu-
Vax and 20 clinical strains (2.08 ± 0.39 × 10-3, Table 2).
Among the clinical strains except for pOka, strain 8 was
the most similar to SuduVax.
Mutations found in SuduVax ORFs
SuduVax ORF0 exists as longer form due to a read-
through mutation. The stop codon TGA (nucleotide
position 388-390) was mutated to CGA coding for Arg.
A putative stop codon TGA was found downstream and
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overlapped with ORF1 (Figure 3). This extended ORF0
encoded a new protein with 221 amino acid residues.
The same read-through mutation was found in other vac-
cine strains, vOka, VarilRix and VariVax. All clinical
strains including pOka contained 390 bp-long ORF0 cod-
ing for 129 amino acids.
Compared to the reference strain Dumas, the lengths
of ORF17 and ORF56 of the strain SuduVax were 3 bp
short due to deletion of TCA at position 367 to 369 and
TCT at position 658 to 660, respectively. Both deletions
resulted in deletion of amino acid S residue. On the
other hand, insertion of three nucleotides ATG at posi-
tion 27 was found in ORF60 of the strain SuduVax.
Interestingly, the aforementioned two deletions and one
insertion were also found in all Oka strains including
pOka. SuduVax as well as Oka strains were found to
have a15 bp (AACATTTCAGGGTCA) shorter ORF29
than most clinical isolates that contain two tandem
reiterations of this 15 bp sequence. Among the clinical
strains, M2DR, CA123 and 8 contained only one copy
of the 15 bp element in ORF29. Strains M2DR and 8
shared the same length for ORF60 with Oka and Sudu-
Vax strains. Table 3 summarizes the insertion and dele-
tion mutations found in SuduVax.
Discussion
VZV strain SuduVax has been used by a Korean pharma-
ceutical company to produce live attenuated vaccine for
chickenpox since 1994. Although its efficacy and safety
have been proven in the marketplace, molecular charac-
teristics of the vaccine strain have not been available. In
this study sequencing and analyses of the nucleotide
sequence of the Korean varicella vaccine strain SuduVax
were undertaken.
In the original paper on the first complete sequencing
of VZV strain Dumas [2], 71 ORFs were proposed. How-
ever, the information obtained from the NCBI GenBank
database for Dumas (NC_001348) identifies 73 ORF if
three ORFs located in TRS are counted as separate ORFs.
Sequencing of two Oka-derived vaccine strains, VarilRix
(DQ008354) and VariVax (DQ008355), identified 72
ORFs [5]. A Blast search using these three strains as
queries produced 74 possible ORFs for VZV. We were
presently able to locate ORF45 (position 81,523- 82,593)
to Dumas and ORF33.5 to VarilRix (position 60,257 -
61,165) and VariVax (60,254 - 61,162). Extended from of
ORF0 due to read-through mutation was identified in
SuduVax as well as in Oka vaccine strains (see below).
Using these reference strains Dumas and VarilRix as
Table 1 Information of the VZV strains analyzed in this study
Strain Accession Number Country Length (bp) %G+C
Genome TRl Ul IRl IRs Us TRs
Dumas NC001348 Netherlands 124,884 88 104,836 88 7,320 5,232 7,320 46.0
M2DR DQ452050 Morocco 124,770 89 104,719 89 7,320 5,232 7,321 46.0
CA123 DQ457052 USA 124,771 100 104,698 98 7,322 5,232 7,321 46.0
SD DQ479953 USA 125,087 88 104,787 88 7,446 5,232 7,446 46.1
Kel DQ479954 USA 125,374 88 104,857 88 7,555 5,232 7,554 46.2
11 DQ479955 Canada 125,370 88 104,906 88 7,529 5,232 7,527 46.2
22 DQ479956 Canada 124,868 88 104,689 88 7,386 5,232 7,385 46.0
03-500 DQ479957 Canada 125,239 88 105,299 88 7,266 5,232 7,266 46.1
36 DQ479958 Canada 125,030 88 104,850 88 7,387 5,232 7,385 46.1
49 DQ479959 Canada 125,041 88 104,916 88 7,358 5,232 7,359 46.1
8 DQ479960 Canada 125,451 89 105,020 88 7,510 5,232 7,512 46.2
32p5 DQ479961 USA 124,945 88 104,760 88 7,389 5,232 7,388 46.1
32p22 DQ479962 USA 125,084 88 104,791 88 7,443 5,232 7,442 46.1
32p72 DQ479963 USA 125,169 88 104,870 88 7,446 5,232 7,445 46.1
NH29_3 DQ674250 USA 124,811 87 104,766 87 7,320 5,230 7,321 46.0
SVETA EU154348 Russia 124,813 87 104,772 87 7,319 5,230 7,318 46.0
MSP AY548170 USA 124,883 88 104,848 88 7,313 5,232 7,314 46.0
BC AY548171 Canada 125,459 88 105,326 88 7,363 5,231 7,363 46.2
HJ0 AJ871403 Germany 124,928 89 104,752 89 7,335 5,230 7,433 46.0
pOka AB097933 Japan 125,125 88 104,798 88 7,463 5,225 7,463 46.1
vOka AB097932 Japan 125,078 88 104,822 88 7,427 5,232 7,421 46.1
VarilRix DQ008354 Japan 124,821 88 104,761 88 7,326 5,231 7,327 46.1
VariVax DQ008355 Japan 124,815 88 104,758 88 7,324 5,232 7,325 46.1
SuduVax This study Korea 124,759 88 104,799 88 7,276 5,232 7,276 46.1
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queries, we were able to identify and locate 74 ORFs in
the genome of the strain SuduVax as well as in other 23
VZV strains analyzed in this study.
Phylogenetic analysis using the full nucleotide
sequences of 24 VZV strains identified five distinct
clades, consistent with previous findings [9,10]. Phyloge-
netic trees constructed with concatenated amino acid
sequences and coding nucleotide sequences also
revealed five clades with the same members. The tree
built using non-coding nucleotide sequences appeared
Figure 1 ORF map of the VZV strain SuduVax. The direction of the arrows indicates the direction of transcription.
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similar to the other trees, except that the strains 8 and
M2DR did not form a clear clade as in other trees.
SuduVax co-clustered with Oka strains and this clade
consisted exclusively of isolates from Japan and Korea in
clade 2. SuduVax shares the minimum complement of
single nucleotide polymorphism at 27 positions [10]
with other members of the clade 2. Various genotyping
methods using limited genetic information of VZV
strains have been proved to represent genotyping using
full genome information [11-15]. Any genotyping
method unequivocally placed SuduVax to the same gen-
ogroup with Oka strains as in phylogenetic trees based
on full or near-full genetic information (data not
shown).
It is not presently certain, because of the lack of full
genome sequences from other Asian isolates, whether
this clade 2 could be extended to include isolates from
other Asian countries or whether it is confined to isolates
from Japan and Korea only. However, available data
based on partial nucleotide sequences or restriction frag-
ment length polymorphism suggest that all Korean iso-
lates and Chinese isolates form a clade with Japanese
isolates [16,17]. Thus, it is possible that the clade 2 could
be extended to include China, which is geographically
close to Japan and Korea.
Coding sequences occupy approximately 91% of the
VZV genome and reflect most of the sequence informa-
tion of the whole genome. Thus, it was expected that the
phylogenetic trees based on the coding sequences are very
similar to the trees based on the full nucleotide sequences.
We found that the coding sequence trees and amino acid
trees were similar to the full nucleotide trees. Noncoding
sequences were found to be interspersed between coding
sequences or ORFs, accounting for approximately 9% of
the VZV genome. The phylogenetic trees based on VZV
noncoding sequences are not different from those based
on full or coding nucleotide sequences or amino acid
sequences. One notable difference is the location of pOka
Figure 2 Phylogenetic analysis of 24 VZV strains. Nucleotide or amino acid sequences were multiple-aligned using ClustalW program (ver
2.0.1) and the resulting *.phy files were used to construct phylogenetic trees using maximum-likelihood (ML) or neighbor-joining (NJ) methods
in Phylip package (version 3.69). (a) ML tree based on full nucleotide sequences. (b) ML tree based on non-coding sequences. (c) NJ tree based
on the nucleotide sequences of ORF62, showing clear separation of vaccine strains from pOka within clade 2. (d) NJ tree based on the
nucleotide sequences of ORF1. Vaccine strains are separated from clinical strains, but formation of clade 2 is not evident.
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within clade 2. In full or coding sequence trees, pOka was
separated from four vaccine strains to form two indepen-
dent subclades within clade 2. On the contrary, pOka did
not form a subclade separated from vaccine strains in non-
coding sequence trees. pOka is a clinical strain. Thus, cod-
ing sequences or amino acid sequences of VZV genome
may provide information distinguishing vaccine strains
from clinical strains, while noncoding sequences does not.
Phylogenetic analyses using the nucleotide sequences
of individual ORFs suggested 12 ORFs may be impor-
tant in distinguishing vaccine strains from clinical
strains. Yamanish identified 23 ORFs that are different
between pOka and Oka vaccine [6], including 12 ORFs
identified in this study. Moreover, our preliminary stu-
dies of single nucleotide polymorphism among the full
genomic DNA sequences of the 24 VZV strains revealed
12 ORFs that may be characteristic for vaccine strains
and these 12 ORFs coincide with the above-mentioned
12 ORFs [manuscript in preparation].
ORF0, also known as ORFS/L, is thought to be essen-
tial for VZV growth and encodes a membrane protein
with 129 amino acid residues, which is possibly involved
in vesicular trafficking and altering cell adhesion mole-
cules in infected cells [18,19]. ORF0 in SuduVax was
determined to possess an extended C-terminal sequence
due to a read-through mutation of its original stop
codon TGA to CGA coding for Arg. The nearest down-
stream stop codon TGA was found to overlap with
ORF1 and the extended ORF0 is expected to code for a
new protein with 221 amino acid residues. Interestingly,
this read-through mutation was also found in the three
Oka-derived vaccine strains, while the stop codons were
found to be unaltered in all of the clinical strains includ-
ing the parent Oka strain. In cells infected with vOka,
the extended form of ORF0 protein with 221 amino
acid residues and its spliced form with 155 amino acid
residues are expressed [20]. Since other vaccine strains,
including SuduVax, share 100% identical nucleotide
sequences within and downstream of ORF0 up to the
new stop codon, both forms of the extended ORF0 pro-
teins are expected to be expressed in permissive cells
infected with SuduVax. Thus, read-through mutation in
ORF0 might be an important feature distinguishing vac-
cine strains from clinical strains.
Besides the read-through mutation in ORF0, SuduVax
share same mutational events in ORFs 17, 29, 56 and 60
with Oka strains. ORF17 codes for an mRNA-specific
RNase [21] and ORF29 encodes single strand DNA
binding protein via its zinc-finger domain [22]. The
function of ORF56 has not been well characterized, but
its gene product is reported to co-localize with regula-
tory protein ICP22 and nuclear protein UL3 in small,
dense nuclear bodies (NCBI, http://www.ncbi.nlm.nih.
gov/pubmed?Db=gene&Cmd=retrieve&dopt=full_repor-
t&list_uids=1487683. The gene product of ORF60 is gly-
coprotein L, which acts as a chaperon for glycoprotein
H [23]. Three bp deletions were found in ORFs 17 and
56, and an insertion of 3-bp was found in ORF60. While
most of the clinical strains contain two tandem copies of
15 bp (AACATTTCAGGGTCA) elements in ORF29,
while the SuduVax and Oka strains contain only one
copy of this 15 bp element. Of these four deletion and
insertion events, two events (ORFs 29, 60) are shared
with the clinical strains 8 and M2DR, and one event
(ORF29) is also found in the strain CA123. Since these
deletion and insertion events are also found in some of
the clinical strains including pOka, they by themselves
may not be important in attenuation, although it is still
possible that they, in combination with other events
such as read-through mutation in ORF0, may play some
roles in attenuation of vaccine strains.
Conclusion
We obtained and analyzed full nucleotide sequence of
the Korean vaccine strain SuduVax. SuduVax was
shown to be genetically most similar to Oka-derived
Table 2 Genetic distances between SuduVax and other
VZV strains
Nucleotide (×10-3) Amino acid (×10-3)
Strains Full Noncoding
Dumas 2.31 3.79 3.09
M2DR 1.87 2.77 2.57
CA123 2.34 3.50 2.75
SD 2.24 2.84 3.04
Kel 2.26 2.70 3.27
11 2.10 3.87 3.09
22 2.12 4.08 2.96
03-500 2.30 3.80 2.80
36 2.18 2.63 3.06
49 2.18 2.70 4.49
8 1.83 2.19 2.35
32p5 2.14 2.77 3.09
32p22 2.19 2.77 4.27
32p72 2.26 2.70 5.03
NH29_3 2.11 3.13 2.85
SVETA 2.15 3.43 3.01
MSP 2.21 3.35 2.93
BC 2.11 2.62 3.09
HJ0 2.20 4.00 2.98
pOka 0.53 0.58 0.97
vOka 0.19 0.15 0.57
VarilRix 0.16 0.07 0.47
VariVax 0.25 0.44 0.63
Average
Vaccine 0.20 0.22 0.56
Clinical 2.08 3.01 3.08
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vaccine strains. We are now comparing the SuduVax
nucleotide and amino acid sequences with those of
other vaccine and clinical strains. Further comparative
genomic and bioinformatics analyses will help to eluci-
date the molecular basis of the attenuation of the VZV
vaccine strains.
Materials and methods
Virus and DNA sequencing
DNA of the VZV strain SuduVax was extracted from
commercial vials of SuduVax™ with QIAamp DNA
Mini Kit (QIAGEN) at a concentration of 5.5 μg/100
μL. The DNA sequence was determined by the high
throughput sequencing method using a Genome
Sequencer FLX Titanium System of Roche Diagnostics,
serviced by Macrogen. Sequence fragments (n =
23,722) with an average length of approximately 400
bp were obtained and these were assembled and
viewed using the Consed program http://bozeman.mbt.
washington.edu/consed/consed.html. The average qual-
ity of the sequence fragments was more than 99.99%.
A total of 99.38% of the 124,759 sequences aligned
with the derived consensus sequence and the average
coverage was 83 reads per nucleotide. These were
aligned against reference strain Dumas (NC_001348)
and vaccine strain VarilRix (DQ008354). The gaps
between the contigs were filled by polymerase chain
reaction sequencing using primers whose sequences
were obtained from the adjacent contigs. The com-
pleted sequence was deposited into NCBI GenBank
(accession number JF306641).
Allocation of ORFs
ORFs of the strain SuduVax in the full genome
sequence was located by Blast search against two refer-
ence strains Dumas (NC_001348) and VarilRix
(DQ008354). Complementary determining sequences
Figure 3 Read-through mutation in ORF0 of SuduVax and Oka vaccine strains. ORF0 sequences of 24 VZV strains were extracted and
aligned using the ClustalW program. Substitution of T388C and putative downstream new stop codon TGA are shaded.
Table 3 Deletions and insertion found in SuduVax
Mutation Nucleotide Amino
acid
ORF Also found in
Deletion TCA S ORF17 4Oka1
AACATTTCAGGGTCA NISGS ORF29 4Oka, M2DR,
CA123, 8
TCT S ORF56 4Oka
Insertion ATG M ORF60 4Oka, M2DR, 8
1pOka, vOka, VariVax, and VarilRix
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(CDSs) of the reference strains were extracted using
FeatureExtract 1.2 Server program http://www.cbs.dtu.
dk/services/FeatureExtract/ and used as query. The
resulting data included the first and last nucleotide posi-
tions of the each ORF in the strain SuduVax genome
and direction of the ORFs. The ORF information was veri-
fied by ORF finding programs such as CLC Sequence
Viewer (version 6.4, http://www.clcbio.com/index.php)
and ORF Finder provided by NCBI. When the results of
Blast search did not coincide with those of ORF finding
programs, the nucleotide sequences of the corresponding
ORFs were examined with BioEdit Sequence Alignment
Editor (Department of Microbiology, North Carolina State
University, version 7.0.5.3, http://www.mbio.ncsu.edu/
BioEdit/bioedit.html) and manually edited to locate the
position of the start and stop codons. Finally all the allo-
cated ORFs were confirmed by identification of the trans-
lated amino acid sequences.
Phylogenetic analysis
Nucleotide sequences of the VZV full genome other than
SuduVax were obtained directly from GenBank database
(Table 1). For each VZV strain, all ORF sequences were
cut and pasted to generate a concatenated coding
sequence. Similarly, all inter-ORF sequences were cut and
pasted to build a concatenated noncoding sequence.
Amino acid sequences were obtained by translation of the
corresponding ORFs and pasted to generate a concate-
nated sequence harbouring all 74 ORFs. These full or con-
catenated nucleotide or concatenated amino acid
sequence of the 24 VZV strains were multiple-aligned
using the ClustalW program (ver 2.0.1) followed by man-
ual editing. The resulting out-files were used to calculate
genetic distances using Dnadist (for nucleotide) or Protdist
(for amino acid) program included in Phylip package (ver-
sion 3.69, http://evolution.genetics.washington.edu/phylip.
html). Distance matrix was obtained by Kimura-2-para-
meter for nucleotide or Jones-Taylor-Thornton method
for amino acid. Cluster analysis was performed by neigh-
bour-joining (NJ) and maximum-likelihood (ML) method
and resulting tree files were viewed by Treeview program
(version 1.6.6). The significance of the phylogenetic trees
was verified by bootstrap analysis. Phylogenetic trees were
constructed from 1,000 replicates generated by the Seq-
boot program and the consensus tree was identified by the
Consense program.
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